# Jianxin Capital

> Jianxin Capital is a VC fund backing Health Care and Biotechnology. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 13
- Last investment: Mar 2024
- Lead investor: 8%
- Last updated: Aug 2026
- Website: http://jianxincapital.com/

Jianxin Capital is a VC fund in Shanghai focused on Health Care and Biotechnology. Shanghai Jianxin equity is a Cci Capital Ltd focused on healthcare industry risk investment fund, has a professional investment team, the team has rich medical and financial investment, management and entrepreneurial experience, can make prospective investment layout according to the development trend of the industry, creating value for enterprisesand investors. The company has a team of nearly 20 professional investment team, they were from medical institutions and financial class at home and abroad, with senior biomedical and financial professional background, have rich human resources in the field, the trend of development, familiar with domestic and international bio pharmaceutical industry research and development dynamics, can focus on the invested enterprise demand for product development, industrialization, management and financial investment and a full range of value-added services.

## Contacts

5 contacts available for Jianxin Capital. Shizune tracks 1 team members at Jianxin Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/jianxin-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 38% |
| Biotechnology | 5 | 38% |
| Manufacturing | 4 | 31% |
| Pharmaceutical | 4 | 31% |
| Sales | 2 | 15% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 46% |
| Series B | 2 | 15% |
| Series C | 2 | 15% |
| Angel | 1 | 8% |
| Series D | 1 | 8% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Quanhong Yuan | Chief Executive Officer & President | 7 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hegea Bio | Hegeia Biotechnology is a company that focused on the research and development of siRNA, tiny nucleic acid attached delivery medicines. | $13.8M | Series A | Mar 28, 2024 |  |
| Isabers | Isabers is a provider of advanced semiconductor integration technology and products, which can achieve inter-generational fusion of semiconductor materials and advanced packaging and can effectively solve the pain points of low yield, high cost, and limited performance of advanced semiconductor materials or devices, thus accelerating thedevelopment of the domestic semiconductor industry and quickly seizing the strategic high ground of international market competition. | $31.3M | Series A | May 18, 2023 |  |
| Meike Solar | Meike Solar focuses on the research and development of solar photovoltaic polycrystalline silicon wafers and operates integrated monitoring systems and equipment to facilitate intelligent manufacturing processes, permitting itself to make products efficiently at a reduced cost. | $188.3M | Series B | Dec 21, 2021 |  |
| Weishi Energy | Weishi Energy is a hydrogen fuel cell product research and development manufacturer, focusing on the market operation of hydrogen fuel cell technology, and is committed to promoting the low-carbon sustainable development of human energy. It is mainly engaged in the research and development, production and sales of hydrogen fuel cell products. Atpresent, Weishi Energy has deployed five R&D centers in Shanghai, Baoding, Japan, Germany, and Canada. It has established a culturally diverse and technologically advanced R&D team, and strictly follows the V model development process to create vehicle-level fuel cell power systems and components. The company's main products include fuel cell engines, electric stacks, 35MPa/70MPa on-board hydrogen systems, bottle valves and pressure reducing valves, etc. | $141.3M | Series A | Dec 14, 2021 |  |
| Abbisko Therapeutics | Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China. | $70M | Series C | Mar 25, 2020 |  |
| Percutek Therapeutics | Percutek Therapeutics is a cardiovascular interventional device research and development manufacturer, mainly engaged in the research and development and production of cardiac and vascular related Class III minimally invasive interventional medical devices, dedicated to providing patients with safe interventional devices for cardiovascular clinicalMedical solutions, etc. | $14.2M | Series D | Jun 24, 2019 |  |
| Innocare | InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. InnoCare' s core scientific team members have strong educational backgrounds and rich drug innovation experiences in the U.S. and China. InnoCare also has an elite Scientific Advisory Board(SAB) comprising of professionals from leading universities, hospitals, academic institutions and pharmaceutical industry. InnoCare is forging forward on the critical path of defeating diseases and pushing the boundaries of innovation into unchartered territories. | $160M | Private Equity | Jan 03, 2019 |  |
| Sumgen Biotech | Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . | $7.1M | Series A | Jul 27, 2018 |  |
| Eastern Biotech | Eastern Biotech engages in the development and manufacturing of pharmaceutical products. | $425K | Angel | Feb 06, 2018 |  |
| Leads Biolabs | Leads Biolabs is a pharmaceutical company that develops medicines and treatments for tumors. |  | Series A | Jul 03, 2017 |  |

10 of 13 investments shown.

## Co-investors
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Loyal Valley Capital](https://shizune.co/investors/profile/loyal-valley-capital) — VC Fund, 2 deals together
- [ABC Capital](https://shizune.co/investors/profile/abccapital) — VC Fund, 1 deal together
- [Beijing E-town International Investment & Development](https://shizune.co/investors/profile/beiid) — VC Fund, 1 deal together
- [Beijing Financial Street Capital Operation Center](https://shizune.co/investors/profile/beijing-financial-street-capital-operation-center) — VC Fund, 1 deal together
- [Beijing Hankang Chuangye Touzi](https://shizune.co/investors/profile/beijing-hankang-chuangye-touzi) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jianxin Capital invest in?

Jianxin Capital invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Series B stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jianxin Capital?

Public channels for Jianxin Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Jianxin Capital?

The team at Jianxin Capital includes Quanhong Yuan (Chief Executive Officer & President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co